| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| HIV Infections | 152 | 2024 | 2158 | 18.200 |
Why?
|
| Medication Adherence | 25 | 2020 | 519 | 5.070 |
Why?
|
| Anti-HIV Agents | 29 | 2018 | 353 | 4.900 |
Why?
|
| Patient Compliance | 24 | 2018 | 678 | 4.080 |
Why?
|
| Patient Acceptance of Health Care | 22 | 2018 | 602 | 3.660 |
Why?
|
| Viral Load | 23 | 2020 | 482 | 3.070 |
Why?
|
| Antiretroviral Therapy, Highly Active | 28 | 2015 | 309 | 3.070 |
Why?
|
| Health Services Accessibility | 15 | 2019 | 817 | 2.640 |
Why?
|
| Continuity of Patient Care | 9 | 2018 | 221 | 2.550 |
Why?
|
| AIDS Serodiagnosis | 9 | 2019 | 57 | 2.530 |
Why?
|
| Mass Screening | 19 | 2022 | 1550 | 2.410 |
Why?
|
| Patient-Centered Care | 8 | 2020 | 326 | 2.310 |
Why?
|
| Trust | 7 | 2017 | 108 | 2.080 |
Why?
|
| Physician-Patient Relations | 9 | 2018 | 740 | 2.010 |
Why?
|
| Delivery of Health Care | 13 | 2020 | 876 | 1.840 |
Why?
|
| HIV | 9 | 2024 | 236 | 1.790 |
Why?
|
| Anti-Retroviral Agents | 10 | 2020 | 145 | 1.720 |
Why?
|
| Primary Health Care | 12 | 2019 | 847 | 1.680 |
Why?
|
| Health Knowledge, Attitudes, Practice | 15 | 2018 | 1233 | 1.620 |
Why?
|
| CD4 Lymphocyte Count | 22 | 2019 | 296 | 1.620 |
Why?
|
| HIV Seropositivity | 5 | 2012 | 154 | 1.570 |
Why?
|
| Hospitalization | 9 | 2019 | 2180 | 1.530 |
Why?
|
| Texas | 38 | 2020 | 6444 | 1.470 |
Why?
|
| Health Promotion | 5 | 2017 | 510 | 1.450 |
Why?
|
| Patient Satisfaction | 4 | 2017 | 915 | 1.340 |
Why?
|
| Adult | 116 | 2024 | 82003 | 1.290 |
Why?
|
| Ambulatory Care Facilities | 11 | 2022 | 300 | 1.290 |
Why?
|
| Community Health Centers | 4 | 2014 | 50 | 1.250 |
Why?
|
| Anemia, Sickle Cell | 4 | 2013 | 343 | 1.230 |
Why?
|
| Sexual Behavior | 5 | 2020 | 313 | 1.210 |
Why?
|
| Risk-Taking | 3 | 2020 | 131 | 1.210 |
Why?
|
| Veterans | 15 | 2023 | 1750 | 1.200 |
Why?
|
| Male | 139 | 2024 | 128724 | 1.190 |
Why?
|
| Child Health Services | 3 | 2013 | 89 | 1.130 |
Why?
|
| Social Support | 5 | 2020 | 591 | 1.110 |
Why?
|
| Physicians | 6 | 2022 | 871 | 1.080 |
Why?
|
| Cross-Sectional Studies | 21 | 2023 | 4505 | 1.070 |
Why?
|
| Ambulatory Care | 6 | 2015 | 599 | 1.070 |
Why?
|
| Young Adult | 47 | 2020 | 22190 | 1.070 |
Why?
|
| Female | 126 | 2024 | 149106 | 1.040 |
Why?
|
| Middle Aged | 99 | 2024 | 90422 | 1.030 |
Why?
|
| Disease Transmission, Infectious | 2 | 2018 | 101 | 1.020 |
Why?
|
| Humans | 180 | 2024 | 271550 | 1.010 |
Why?
|
| Peer Group | 3 | 2018 | 142 | 1.000 |
Why?
|
| United States | 54 | 2024 | 16006 | 1.000 |
Why?
|
| Serologic Tests | 3 | 2020 | 150 | 0.960 |
Why?
|
| Homosexuality, Male | 7 | 2020 | 75 | 0.950 |
Why?
|
| Physicians, Primary Care | 2 | 2016 | 107 | 0.910 |
Why?
|
| Hepatitis C | 11 | 2010 | 552 | 0.900 |
Why?
|
| Surveys and Questionnaires | 16 | 2022 | 5936 | 0.880 |
Why?
|
| Communication | 5 | 2022 | 855 | 0.830 |
Why?
|
| Telemedicine | 4 | 2024 | 554 | 0.810 |
Why?
|
| Sexual and Gender Minorities | 2 | 2020 | 76 | 0.810 |
Why?
|
| Adolescent | 46 | 2020 | 32726 | 0.800 |
Why?
|
| Pre-Exposure Prophylaxis | 3 | 2019 | 41 | 0.790 |
Why?
|
| HIV-1 | 7 | 2022 | 641 | 0.790 |
Why?
|
| Quality of Health Care | 3 | 2013 | 629 | 0.780 |
Why?
|
| Cohort Studies | 36 | 2023 | 9477 | 0.760 |
Why?
|
| Appointments and Schedules | 5 | 2015 | 97 | 0.750 |
Why?
|
| Text Messaging | 2 | 2019 | 36 | 0.730 |
Why?
|
| Health Care Surveys | 7 | 2016 | 424 | 0.720 |
Why?
|
| Staphylococcal Skin Infections | 1 | 2020 | 45 | 0.700 |
Why?
|
| Substance-Related Disorders | 4 | 2021 | 548 | 0.690 |
Why?
|
| Health Services Needs and Demand | 4 | 2019 | 248 | 0.690 |
Why?
|
| Soft Tissue Infections | 1 | 2020 | 94 | 0.650 |
Why?
|
| Chronic Disease | 2 | 2015 | 1847 | 0.640 |
Why?
|
| Early Medical Intervention | 2 | 2016 | 32 | 0.640 |
Why?
|
| Insurance, Health | 2 | 2018 | 262 | 0.620 |
Why?
|
| Community-Acquired Infections | 2 | 2020 | 286 | 0.610 |
Why?
|
| Health Services | 2 | 2015 | 101 | 0.600 |
Why?
|
| Dementia | 1 | 2023 | 479 | 0.600 |
Why?
|
| Unsafe Sex | 1 | 2017 | 21 | 0.600 |
Why?
|
| Community Health Workers | 4 | 2015 | 59 | 0.600 |
Why?
|
| Patient Participation | 2 | 2019 | 456 | 0.590 |
Why?
|
| Infectious Disease Transmission, Vertical | 4 | 2015 | 239 | 0.590 |
Why?
|
| Office Visits | 2 | 2019 | 94 | 0.580 |
Why?
|
| Survivors | 2 | 2015 | 1023 | 0.580 |
Why?
|
| Practice Guidelines as Topic | 4 | 2018 | 2422 | 0.580 |
Why?
|
| Methicillin-Resistant Staphylococcus aureus | 1 | 2020 | 290 | 0.570 |
Why?
|
| Hospitals, Pediatric | 2 | 2013 | 794 | 0.560 |
Why?
|
| Interviews as Topic | 6 | 2019 | 527 | 0.560 |
Why?
|
| Behavior Therapy | 5 | 2016 | 304 | 0.560 |
Why?
|
| Internal Medicine | 1 | 2018 | 160 | 0.550 |
Why?
|
| Attitude to Health | 5 | 2018 | 439 | 0.550 |
Why?
|
| Prospective Studies | 17 | 2023 | 13385 | 0.550 |
Why?
|
| Cognition | 1 | 2022 | 970 | 0.540 |
Why?
|
| Mentors | 3 | 2016 | 210 | 0.540 |
Why?
|
| Patient Outcome Assessment | 2 | 2022 | 246 | 0.540 |
Why?
|
| Alzheimer Disease | 1 | 2023 | 828 | 0.520 |
Why?
|
| Counseling | 1 | 2018 | 382 | 0.520 |
Why?
|
| Hospitals, Veterans | 3 | 2017 | 376 | 0.510 |
Why?
|
| Program Evaluation | 6 | 2019 | 611 | 0.500 |
Why?
|
| Reverse Transcriptase Inhibitors | 3 | 2011 | 55 | 0.490 |
Why?
|
| Sickness Impact Profile | 1 | 2015 | 138 | 0.490 |
Why?
|
| Urban Population | 6 | 2023 | 280 | 0.480 |
Why?
|
| Socioeconomic Factors | 7 | 2015 | 1260 | 0.480 |
Why?
|
| Communication Barriers | 1 | 2014 | 52 | 0.470 |
Why?
|
| Community Health Services | 3 | 2018 | 129 | 0.470 |
Why?
|
| Veterans Health | 1 | 2016 | 176 | 0.470 |
Why?
|
| Health Education | 3 | 2015 | 303 | 0.460 |
Why?
|
| Marketing of Health Services | 1 | 2014 | 33 | 0.460 |
Why?
|
| Guideline Adherence | 2 | 2018 | 643 | 0.450 |
Why?
|
| Reminder Systems | 2 | 2011 | 85 | 0.450 |
Why?
|
| Emergency Service, Hospital | 6 | 2018 | 1238 | 0.450 |
Why?
|
| Role | 1 | 2013 | 47 | 0.450 |
Why?
|
| Anxiety | 3 | 2021 | 1234 | 0.440 |
Why?
|
| Patient Selection | 3 | 2017 | 2033 | 0.440 |
Why?
|
| Qualitative Research | 7 | 2019 | 645 | 0.440 |
Why?
|
| Psychometrics | 2 | 2015 | 962 | 0.430 |
Why?
|
| Social Marketing | 1 | 2013 | 14 | 0.430 |
Why?
|
| Protease Inhibitors | 2 | 2015 | 207 | 0.420 |
Why?
|
| Practice Patterns, Physicians' | 3 | 2018 | 1317 | 0.420 |
Why?
|
| Hospitals, Urban | 2 | 2015 | 99 | 0.410 |
Why?
|
| Public Health | 2 | 2016 | 296 | 0.400 |
Why?
|
| Syphilis, Cutaneous | 1 | 2011 | 9 | 0.390 |
Why?
|
| Patient Preference | 1 | 2014 | 228 | 0.390 |
Why?
|
| Retrospective Studies | 40 | 2023 | 39818 | 0.390 |
Why?
|
| Hospitals, General | 1 | 2011 | 32 | 0.380 |
Why?
|
| Healthcare Disparities | 4 | 2014 | 656 | 0.380 |
Why?
|
| Depression | 6 | 2022 | 1730 | 0.380 |
Why?
|
| Delayed Diagnosis | 1 | 2013 | 152 | 0.380 |
Why?
|
| Aged | 37 | 2023 | 73451 | 0.380 |
Why?
|
| Skin Ulcer | 1 | 2011 | 73 | 0.380 |
Why?
|
| Sexually Transmitted Diseases, Viral | 1 | 2010 | 5 | 0.380 |
Why?
|
| Disabled Children | 1 | 2011 | 28 | 0.370 |
Why?
|
| Lost to Follow-Up | 3 | 2022 | 33 | 0.370 |
Why?
|
| Parent-Child Relations | 1 | 2013 | 266 | 0.370 |
Why?
|
| Poverty | 3 | 2015 | 477 | 0.370 |
Why?
|
| Inpatients | 2 | 2017 | 697 | 0.370 |
Why?
|
| Syphilis | 1 | 2011 | 98 | 0.360 |
Why?
|
| Glucosephosphate Dehydrogenase Deficiency | 1 | 2010 | 14 | 0.360 |
Why?
|
| Interpersonal Relations | 1 | 2012 | 277 | 0.360 |
Why?
|
| Language | 1 | 2013 | 327 | 0.360 |
Why?
|
| Communications Media | 1 | 2010 | 5 | 0.350 |
Why?
|
| Risk Factors | 18 | 2022 | 17982 | 0.340 |
Why?
|
| Clinical Laboratory Techniques | 1 | 2011 | 207 | 0.340 |
Why?
|
| Pregnancy Complications, Infectious | 2 | 2015 | 432 | 0.340 |
Why?
|
| Motivation | 1 | 2013 | 516 | 0.330 |
Why?
|
| Drug Monitoring | 1 | 2011 | 352 | 0.330 |
Why?
|
| Self Administration | 2 | 2011 | 58 | 0.330 |
Why?
|
| Sierra Leone | 4 | 2018 | 30 | 0.330 |
Why?
|
| Itraconazole | 1 | 2009 | 81 | 0.330 |
Why?
|
| Health Personnel | 2 | 2014 | 657 | 0.320 |
Why?
|
| Histoplasmosis | 1 | 2009 | 80 | 0.320 |
Why?
|
| Vascular Diseases | 1 | 2011 | 242 | 0.320 |
Why?
|
| Multivariate Analysis | 9 | 2015 | 4337 | 0.300 |
Why?
|
| Emergency Medical Services | 1 | 2013 | 469 | 0.300 |
Why?
|
| Electronic Health Records | 4 | 2024 | 973 | 0.300 |
Why?
|
| Pain Measurement | 4 | 2014 | 1016 | 0.290 |
Why?
|
| Lymphoma, Non-Hodgkin | 2 | 2019 | 1067 | 0.290 |
Why?
|
| Alcoholism | 2 | 2023 | 329 | 0.290 |
Why?
|
| Quality of Life | 4 | 2015 | 4764 | 0.280 |
Why?
|
| Anus Neoplasms | 4 | 2015 | 417 | 0.280 |
Why?
|
| Internship and Residency | 1 | 2018 | 1441 | 0.280 |
Why?
|
| Pilot Projects | 5 | 2024 | 2857 | 0.270 |
Why?
|
| Regression Analysis | 4 | 2015 | 1578 | 0.270 |
Why?
|
| Smoking Cessation | 2 | 2024 | 768 | 0.270 |
Why?
|
| Time Factors | 9 | 2018 | 13077 | 0.270 |
Why?
|
| Sleep Wake Disorders | 3 | 2014 | 373 | 0.270 |
Why?
|
| Self Efficacy | 3 | 2013 | 300 | 0.260 |
Why?
|
| Reproducibility of Results | 5 | 2021 | 6205 | 0.260 |
Why?
|
| Health Plan Implementation | 2 | 2018 | 90 | 0.260 |
Why?
|
| Public Health Practice | 2 | 2016 | 24 | 0.260 |
Why?
|
| Randomized Controlled Trials as Topic | 5 | 2024 | 2659 | 0.260 |
Why?
|
| Prisoners | 4 | 2010 | 34 | 0.250 |
Why?
|
| Carcinoma, Hepatocellular | 3 | 2009 | 2163 | 0.250 |
Why?
|
| Medicare | 4 | 2023 | 932 | 0.250 |
Why?
|
| Prevalence | 8 | 2015 | 3413 | 0.240 |
Why?
|
| Self Report | 3 | 2021 | 792 | 0.240 |
Why?
|
| Patient Education as Topic | 4 | 2019 | 745 | 0.240 |
Why?
|
| Lymphoproliferative Disorders | 1 | 2007 | 382 | 0.230 |
Why?
|
| Infant | 9 | 2015 | 13969 | 0.230 |
Why?
|
| Neuropsychological Tests | 3 | 2023 | 1146 | 0.230 |
Why?
|
| Pediatrics | 1 | 2013 | 1190 | 0.230 |
Why?
|
| Bile Duct Neoplasms | 1 | 2009 | 498 | 0.230 |
Why?
|
| Databases, Factual | 1 | 2011 | 2282 | 0.230 |
Why?
|
| Patient Care | 2 | 2016 | 151 | 0.220 |
Why?
|
| Cholangiocarcinoma | 1 | 2009 | 501 | 0.220 |
Why?
|
| Treatment Outcome | 14 | 2016 | 33870 | 0.220 |
Why?
|
| Cell Phone | 2 | 2014 | 43 | 0.210 |
Why?
|
| Internet | 1 | 2007 | 704 | 0.210 |
Why?
|
| Mobile Applications | 1 | 2024 | 109 | 0.210 |
Why?
|
| Logistic Models | 4 | 2015 | 3455 | 0.210 |
Why?
|
| Creativity | 1 | 2022 | 14 | 0.210 |
Why?
|
| Eosinophilia | 2 | 2014 | 184 | 0.210 |
Why?
|
| Parents | 3 | 2015 | 1079 | 0.210 |
Why?
|
| Child, Preschool | 7 | 2015 | 17039 | 0.200 |
Why?
|
| HIV Antibodies | 2 | 2022 | 95 | 0.190 |
Why?
|
| Executive Function | 1 | 2022 | 143 | 0.190 |
Why?
|
| Health Policy | 2 | 2014 | 282 | 0.190 |
Why?
|
| Rural Population | 1 | 2023 | 292 | 0.190 |
Why?
|
| Culture | 2 | 2012 | 104 | 0.190 |
Why?
|
| Liver Cirrhosis | 3 | 2007 | 1034 | 0.190 |
Why?
|
| Attitude of Health Personnel | 3 | 2018 | 920 | 0.190 |
Why?
|
| Liver Neoplasms | 3 | 2009 | 4807 | 0.190 |
Why?
|
| Disabled Persons | 1 | 2022 | 112 | 0.190 |
Why?
|
| Trypanosoma cruzi | 1 | 2024 | 233 | 0.180 |
Why?
|
| Staphylococcus aureus | 2 | 2020 | 561 | 0.180 |
Why?
|
| Child | 9 | 2016 | 30545 | 0.180 |
Why?
|
| Housing | 1 | 2020 | 67 | 0.180 |
Why?
|
| Emigrants and Immigrants | 2 | 2013 | 159 | 0.180 |
Why?
|
| Chagas Disease | 1 | 2024 | 288 | 0.170 |
Why?
|
| Mentoring | 1 | 2022 | 102 | 0.170 |
Why?
|
| Prisons | 2 | 2010 | 12 | 0.170 |
Why?
|
| Social Stigma | 1 | 2020 | 74 | 0.170 |
Why?
|
| Longitudinal Studies | 4 | 2019 | 2058 | 0.170 |
Why?
|
| Early Diagnosis | 2 | 2014 | 316 | 0.170 |
Why?
|
| Thyroid Neoplasms | 2 | 2007 | 1884 | 0.160 |
Why?
|
| Mycobacterium tuberculosis | 1 | 2003 | 486 | 0.160 |
Why?
|
| Memory Disorders | 1 | 2021 | 289 | 0.160 |
Why?
|
| Hyperaldosteronism | 1 | 2019 | 30 | 0.160 |
Why?
|
| Psychiatric Status Rating Scales | 2 | 2012 | 901 | 0.160 |
Why?
|
| House Calls | 1 | 2018 | 40 | 0.160 |
Why?
|
| Chicago | 1 | 2018 | 40 | 0.160 |
Why?
|
| HIV Core Protein p24 | 1 | 2018 | 18 | 0.150 |
Why?
|
| HIV Serosorting | 1 | 2017 | 1 | 0.150 |
Why?
|
| Intention | 3 | 2013 | 114 | 0.150 |
Why?
|
| Condoms | 1 | 2017 | 50 | 0.150 |
Why?
|
| Health Communication | 1 | 2018 | 36 | 0.150 |
Why?
|
| Minority Health | 1 | 2017 | 16 | 0.150 |
Why?
|
| Mental Health | 1 | 2021 | 412 | 0.150 |
Why?
|
| Waiting Lists | 1 | 2019 | 266 | 0.140 |
Why?
|
| Factor Analysis, Statistical | 2 | 2015 | 353 | 0.140 |
Why?
|
| Alcohol Drinking | 1 | 2020 | 601 | 0.140 |
Why?
|
| Sexual Partners | 1 | 2017 | 103 | 0.140 |
Why?
|
| Linear Models | 2 | 2013 | 1099 | 0.140 |
Why?
|
| Patients | 1 | 2019 | 248 | 0.140 |
Why?
|
| Minority Groups | 2 | 2013 | 327 | 0.140 |
Why?
|
| Tuberculosis | 1 | 2003 | 613 | 0.140 |
Why?
|
| Incidence | 9 | 2015 | 5848 | 0.140 |
Why?
|
| Medically Underserved Area | 1 | 2017 | 122 | 0.140 |
Why?
|
| Drug Therapy, Combination | 3 | 2011 | 2357 | 0.140 |
Why?
|
| Adrenocortical Carcinoma | 1 | 2019 | 191 | 0.130 |
Why?
|
| Risk Assessment | 5 | 2015 | 6845 | 0.130 |
Why?
|
| Perception | 1 | 2018 | 350 | 0.130 |
Why?
|
| Guidelines as Topic | 1 | 2018 | 371 | 0.130 |
Why?
|
| Pain | 2 | 2014 | 1698 | 0.130 |
Why?
|
| Case-Control Studies | 5 | 2018 | 6234 | 0.130 |
Why?
|
| Vulnerable Populations | 1 | 2017 | 188 | 0.130 |
Why?
|
| Self-Assessment | 1 | 2015 | 89 | 0.130 |
Why?
|
| Cities | 1 | 2014 | 57 | 0.120 |
Why?
|
| Clinical Trials as Topic | 2 | 2017 | 3850 | 0.120 |
Why?
|
| Splints | 1 | 2013 | 10 | 0.120 |
Why?
|
| Sex Factors | 3 | 2010 | 2199 | 0.120 |
Why?
|
| Antiviral Agents | 3 | 2010 | 1261 | 0.110 |
Why?
|
| Sensitivity and Specificity | 3 | 2022 | 5185 | 0.110 |
Why?
|
| Survival Analysis | 5 | 2009 | 9307 | 0.110 |
Why?
|
| AIDS-Related Opportunistic Infections | 2 | 2005 | 190 | 0.110 |
Why?
|
| AIDS-Associated Nephropathy | 1 | 2014 | 84 | 0.110 |
Why?
|
| Liver Diseases | 3 | 2007 | 605 | 0.110 |
Why?
|
| Central Nervous System Neoplasms | 1 | 2019 | 549 | 0.110 |
Why?
|
| Visual Analog Scale | 1 | 2013 | 12 | 0.110 |
Why?
|
| Risk | 2 | 2009 | 1943 | 0.110 |
Why?
|
| Professional-Patient Relations | 1 | 2014 | 114 | 0.110 |
Why?
|
| Patient Advocacy | 1 | 2013 | 90 | 0.110 |
Why?
|
| Failure to Thrive | 1 | 2013 | 96 | 0.110 |
Why?
|
| Violence | 1 | 2013 | 126 | 0.110 |
Why?
|
| Carcinoma, Squamous Cell | 4 | 2015 | 5606 | 0.110 |
Why?
|
| Hepatitis C, Chronic | 2 | 2010 | 470 | 0.110 |
Why?
|
| Centralized Hospital Services | 1 | 2012 | 4 | 0.110 |
Why?
|
| Hepacivirus | 3 | 2010 | 424 | 0.100 |
Why?
|
| Follow-Up Studies | 5 | 2016 | 15247 | 0.100 |
Why?
|
| Emtricitabine | 1 | 2012 | 7 | 0.100 |
Why?
|
| Tenofovir | 1 | 2012 | 22 | 0.100 |
Why?
|
| Homosexuality | 2 | 2010 | 30 | 0.100 |
Why?
|
| Benzoxazines | 1 | 2012 | 26 | 0.100 |
Why?
|
| Alkynes | 1 | 2012 | 30 | 0.100 |
Why?
|
| Pneumonia, Pneumococcal | 2 | 2009 | 93 | 0.100 |
Why?
|
| Anti-Bacterial Agents | 2 | 2020 | 3184 | 0.100 |
Why?
|
| Cyclopropanes | 1 | 2012 | 90 | 0.100 |
Why?
|
| Organophosphonates | 1 | 2012 | 63 | 0.100 |
Why?
|
| Motivational Interviewing | 1 | 2012 | 47 | 0.100 |
Why?
|
| Child, Exceptional | 1 | 2011 | 3 | 0.100 |
Why?
|
| Stereotyping | 1 | 2011 | 22 | 0.100 |
Why?
|
| Rural Health | 1 | 2011 | 55 | 0.100 |
Why?
|
| Poisson Distribution | 1 | 2011 | 86 | 0.090 |
Why?
|
| Community-Institutional Relations | 1 | 2011 | 42 | 0.090 |
Why?
|
| Health Surveys | 1 | 2013 | 401 | 0.090 |
Why?
|
| Niacin | 1 | 2011 | 58 | 0.090 |
Why?
|
| Pancreatic Neoplasms | 1 | 2009 | 5252 | 0.090 |
Why?
|
| Family Practice | 1 | 2011 | 132 | 0.090 |
Why?
|
| Spouses | 1 | 2012 | 138 | 0.090 |
Why?
|
| Fenofibrate | 1 | 2011 | 58 | 0.090 |
Why?
|
| Sulfamethizole | 1 | 2010 | 1 | 0.090 |
Why?
|
| Trimethoprim | 1 | 2010 | 7 | 0.090 |
Why?
|
| Genes, pol | 1 | 2010 | 11 | 0.090 |
Why?
|
| Video Recording | 1 | 2013 | 284 | 0.090 |
Why?
|
| Dapsone | 1 | 2010 | 15 | 0.090 |
Why?
|
| Glucosephosphate Dehydrogenase | 1 | 2010 | 25 | 0.090 |
Why?
|
| Adaptation, Psychological | 1 | 2015 | 787 | 0.090 |
Why?
|
| Safe Sex | 1 | 2010 | 19 | 0.090 |
Why?
|
| Aged, 80 and over | 5 | 2017 | 31066 | 0.090 |
Why?
|
| Adiponectin | 1 | 2011 | 144 | 0.090 |
Why?
|
| Peripheral Nervous System Diseases | 1 | 2014 | 409 | 0.090 |
Why?
|
| Anemia, Hemolytic | 1 | 2010 | 54 | 0.090 |
Why?
|
| Drug Resistance, Viral | 1 | 2010 | 70 | 0.090 |
Why?
|
| Focus Groups | 1 | 2011 | 287 | 0.090 |
Why?
|
| Neuralgia | 1 | 2013 | 265 | 0.090 |
Why?
|
| Health Facilities | 1 | 2010 | 78 | 0.090 |
Why?
|
| Costs and Cost Analysis | 1 | 2011 | 311 | 0.090 |
Why?
|
| Life Expectancy | 1 | 2010 | 129 | 0.090 |
Why?
|
| Viremia | 1 | 2010 | 182 | 0.090 |
Why?
|
| ROC Curve | 1 | 2013 | 1250 | 0.090 |
Why?
|
| Disability Evaluation | 1 | 2011 | 239 | 0.090 |
Why?
|
| Risk Reduction Behavior | 1 | 2011 | 216 | 0.090 |
Why?
|
| Needs Assessment | 1 | 2011 | 237 | 0.080 |
Why?
|
| Health Care Costs | 1 | 2015 | 699 | 0.080 |
Why?
|
| Aspartate Aminotransferases | 1 | 2010 | 146 | 0.080 |
Why?
|
| Affect | 1 | 2011 | 306 | 0.080 |
Why?
|
| HIV Reverse Transcriptase | 1 | 2009 | 18 | 0.080 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2019 | 2359 | 0.080 |
Why?
|
| Cost-Benefit Analysis | 1 | 2013 | 968 | 0.080 |
Why?
|
| Alanine Transaminase | 1 | 2010 | 239 | 0.080 |
Why?
|
| Adenine | 1 | 2012 | 669 | 0.080 |
Why?
|
| Pregnancy | 5 | 2015 | 8110 | 0.080 |
Why?
|
| Haemophilus Infections | 1 | 2009 | 109 | 0.080 |
Why?
|
| Anemia, Hemolytic, Autoimmune | 1 | 2009 | 46 | 0.080 |
Why?
|
| Haemophilus influenzae | 1 | 2009 | 159 | 0.080 |
Why?
|
| Drug Combinations | 1 | 2010 | 635 | 0.080 |
Why?
|
| Purpura, Thrombocytopenic, Idiopathic | 1 | 2009 | 78 | 0.080 |
Why?
|
| Pediatric Obesity | 1 | 2013 | 376 | 0.080 |
Why?
|
| Health Resources | 2 | 2014 | 171 | 0.080 |
Why?
|
| Malawi | 3 | 2015 | 388 | 0.080 |
Why?
|
| Physician's Role | 1 | 2010 | 231 | 0.080 |
Why?
|
| Hepatitis B | 2 | 2008 | 274 | 0.080 |
Why?
|
| Dyslipidemias | 1 | 2011 | 243 | 0.080 |
Why?
|
| Drug Prescriptions | 1 | 2010 | 323 | 0.080 |
Why?
|
| Informed Consent | 1 | 2011 | 415 | 0.080 |
Why?
|
| Research | 1 | 2010 | 431 | 0.070 |
Why?
|
| Pneumonia, Bacterial | 1 | 2009 | 135 | 0.070 |
Why?
|
| Disease Management | 1 | 2013 | 1105 | 0.070 |
Why?
|
| Cause of Death | 2 | 2014 | 784 | 0.070 |
Why?
|
| Cryoglobulinemia | 1 | 2007 | 21 | 0.070 |
Why?
|
| Drug Interactions | 1 | 2009 | 582 | 0.070 |
Why?
|
| Hepatitis, Viral, Human | 1 | 2007 | 68 | 0.070 |
Why?
|
| Neurocysticercosis | 1 | 2007 | 28 | 0.070 |
Why?
|
| Pregnancy Complications | 1 | 2012 | 558 | 0.070 |
Why?
|
| International Classification of Diseases | 1 | 2007 | 95 | 0.070 |
Why?
|
| Hyperglycemia | 1 | 2009 | 338 | 0.070 |
Why?
|
| Models, Statistical | 1 | 2013 | 1187 | 0.070 |
Why?
|
| Survival Rate | 3 | 2010 | 12528 | 0.070 |
Why?
|
| Social Class | 1 | 2008 | 322 | 0.070 |
Why?
|
| Metabolic Syndrome | 1 | 2010 | 369 | 0.070 |
Why?
|
| Streptococcus pneumoniae | 1 | 2009 | 404 | 0.070 |
Why?
|
| Infant, Newborn | 3 | 2022 | 8626 | 0.070 |
Why?
|
| Age Factors | 3 | 2011 | 5502 | 0.070 |
Why?
|
| Deoxycytidine | 1 | 2012 | 1390 | 0.070 |
Why?
|
| Disease Progression | 3 | 2019 | 6857 | 0.070 |
Why?
|
| Anti-Infective Agents | 1 | 2010 | 467 | 0.070 |
Why?
|
| Prejudice | 1 | 2006 | 52 | 0.070 |
Why?
|
| United States Department of Veterans Affairs | 2 | 2007 | 677 | 0.070 |
Why?
|
| Medical Records Systems, Computerized | 1 | 2007 | 249 | 0.070 |
Why?
|
| Acute Coronary Syndrome | 1 | 2009 | 243 | 0.070 |
Why?
|
| Odds Ratio | 4 | 2013 | 2325 | 0.060 |
Why?
|
| Urban Health Services | 1 | 2005 | 34 | 0.060 |
Why?
|
| Papanicolaou Test | 1 | 2006 | 130 | 0.060 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 2013 | 852 | 0.060 |
Why?
|
| Asthma | 1 | 2013 | 895 | 0.060 |
Why?
|
| Severity of Illness Index | 3 | 2011 | 4380 | 0.060 |
Why?
|
| Vaginal Smears | 1 | 2006 | 183 | 0.060 |
Why?
|
| Feasibility Studies | 2 | 2022 | 2364 | 0.060 |
Why?
|
| SEER Program | 1 | 2009 | 1051 | 0.060 |
Why?
|
| San Francisco | 1 | 2004 | 24 | 0.060 |
Why?
|
| Uncompensated Care | 1 | 2004 | 11 | 0.060 |
Why?
|
| Osteomyelitis | 1 | 2007 | 260 | 0.060 |
Why?
|
| Medical Records | 1 | 2005 | 446 | 0.060 |
Why?
|
| Liver Failure, Acute | 1 | 2005 | 98 | 0.060 |
Why?
|
| Systemic Inflammatory Response Syndrome | 1 | 2005 | 192 | 0.060 |
Why?
|
| Waldenstrom Macroglobulinemia | 1 | 2007 | 285 | 0.060 |
Why?
|
| Smokers | 1 | 2024 | 151 | 0.050 |
Why?
|
| Telephone | 1 | 2023 | 160 | 0.050 |
Why?
|
| Treatment Refusal | 1 | 2003 | 129 | 0.050 |
Why?
|
| Carcinoma, Papillary | 1 | 2006 | 580 | 0.050 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2010 | 840 | 0.050 |
Why?
|
| Lung Neoplasms | 1 | 2005 | 12032 | 0.050 |
Why?
|
| Brain Neoplasms | 1 | 2019 | 4955 | 0.050 |
Why?
|
| Treatment Failure | 1 | 2005 | 1430 | 0.050 |
Why?
|
| DNA, Bacterial | 1 | 2003 | 605 | 0.050 |
Why?
|
| RNA, Viral | 3 | 2010 | 729 | 0.050 |
Why?
|
| Staphylococcal Infections | 1 | 2007 | 680 | 0.050 |
Why?
|
| Cluster Analysis | 1 | 2003 | 1071 | 0.050 |
Why?
|
| Lebanon | 1 | 2020 | 10 | 0.050 |
Why?
|
| Feedback | 1 | 2022 | 227 | 0.050 |
Why?
|
| Mental Recall | 1 | 2021 | 171 | 0.050 |
Why?
|
| Sustained Virologic Response | 1 | 2020 | 63 | 0.050 |
Why?
|
| Proportional Hazards Models | 3 | 2021 | 5099 | 0.050 |
Why?
|
| Machine Learning | 1 | 2024 | 364 | 0.040 |
Why?
|
| Patient Navigation | 1 | 2020 | 33 | 0.040 |
Why?
|
| Sex Characteristics | 1 | 2003 | 433 | 0.040 |
Why?
|
| Comorbidity | 2 | 2021 | 2416 | 0.040 |
Why?
|
| Mental Disorders | 1 | 2008 | 885 | 0.040 |
Why?
|
| Hospital Mortality | 1 | 2006 | 1289 | 0.040 |
Why?
|
| Data Collection | 2 | 2013 | 625 | 0.040 |
Why?
|
| Activities of Daily Living | 1 | 2023 | 553 | 0.040 |
Why?
|
| Pharmacists | 1 | 2020 | 97 | 0.040 |
Why?
|
| Precancerous Conditions | 1 | 2006 | 1065 | 0.040 |
Why?
|
| Referral and Consultation | 1 | 2005 | 939 | 0.040 |
Why?
|
| Proof of Concept Study | 1 | 2019 | 58 | 0.040 |
Why?
|
| Directly Observed Therapy | 1 | 2018 | 24 | 0.040 |
Why?
|
| Tablets | 1 | 2018 | 56 | 0.040 |
Why?
|
| Health Services Research | 1 | 2019 | 243 | 0.040 |
Why?
|
| Papillomavirus Infections | 1 | 2006 | 1016 | 0.040 |
Why?
|
| Confidence Intervals | 2 | 2009 | 751 | 0.040 |
Why?
|
| Registries | 2 | 2019 | 2223 | 0.040 |
Why?
|
| Uganda | 1 | 2017 | 72 | 0.040 |
Why?
|
| Neoplasms | 2 | 2015 | 15903 | 0.030 |
Why?
|
| Software | 1 | 2024 | 1392 | 0.030 |
Why?
|
| Diagnostic Tests, Routine | 1 | 2018 | 173 | 0.030 |
Why?
|
| Smoking | 1 | 2005 | 2549 | 0.030 |
Why?
|
| District of Columbia | 1 | 2014 | 19 | 0.030 |
Why?
|
| Financial Support | 1 | 2014 | 10 | 0.030 |
Why?
|
| Probability | 2 | 2007 | 885 | 0.030 |
Why?
|
| Walk Test | 1 | 2014 | 43 | 0.030 |
Why?
|
| Program Development | 1 | 2016 | 263 | 0.030 |
Why?
|
| Drug Utilization | 1 | 2015 | 190 | 0.030 |
Why?
|
| Task Performance and Analysis | 1 | 2014 | 135 | 0.030 |
Why?
|
| Pandemics | 1 | 2023 | 1604 | 0.030 |
Why?
|
| Health Behavior | 1 | 2018 | 601 | 0.030 |
Why?
|
| Premedication | 1 | 2013 | 133 | 0.030 |
Why?
|
| Exercise Test | 1 | 2014 | 308 | 0.030 |
Why?
|
| Algorithms | 1 | 2024 | 3925 | 0.030 |
Why?
|
| Outpatient Clinics, Hospital | 1 | 2012 | 98 | 0.030 |
Why?
|
| Community Networks | 1 | 2012 | 45 | 0.030 |
Why?
|
| Standard of Care | 1 | 2014 | 275 | 0.030 |
Why?
|
| Exanthema | 1 | 2014 | 211 | 0.030 |
Why?
|
| Mortality | 1 | 2014 | 352 | 0.030 |
Why?
|
| Predictive Value of Tests | 2 | 2010 | 4976 | 0.020 |
Why?
|
| Decision Making | 1 | 2019 | 1250 | 0.020 |
Why?
|
| Lower Extremity | 1 | 2013 | 286 | 0.020 |
Why?
|
| Sleep | 1 | 2013 | 443 | 0.020 |
Why?
|
| Prognosis | 4 | 2012 | 22524 | 0.020 |
Why?
|
| Sexually Transmitted Diseases | 1 | 2010 | 105 | 0.020 |
Why?
|
| Prenatal Care | 1 | 2012 | 348 | 0.020 |
Why?
|
| Hypolipidemic Agents | 1 | 2011 | 188 | 0.020 |
Why?
|
| Academic Medical Centers | 1 | 2012 | 689 | 0.020 |
Why?
|
| Alabama | 1 | 2009 | 45 | 0.020 |
Why?
|
| Health Planning | 1 | 2009 | 31 | 0.020 |
Why?
|
| Patient Dropouts | 1 | 2009 | 84 | 0.020 |
Why?
|
| Triglycerides | 1 | 2011 | 609 | 0.020 |
Why?
|
| Diabetes Complications | 1 | 2009 | 311 | 0.020 |
Why?
|
| Life Style | 1 | 2011 | 621 | 0.020 |
Why?
|
| Anticholesteremic Agents | 1 | 2010 | 249 | 0.020 |
Why?
|
| Liver Diseases, Alcoholic | 1 | 2007 | 65 | 0.020 |
Why?
|
| Methicillin Resistance | 1 | 2007 | 147 | 0.020 |
Why?
|
| Rifampin | 1 | 2007 | 220 | 0.020 |
Why?
|
| Double-Blind Method | 1 | 2011 | 2588 | 0.020 |
Why?
|
| Liver Function Tests | 1 | 2005 | 186 | 0.010 |
Why?
|
| Vancomycin | 1 | 2007 | 292 | 0.010 |
Why?
|
| Intensive Care Units | 1 | 2009 | 738 | 0.010 |
Why?
|
| Infusions, Intravenous | 1 | 2007 | 1437 | 0.010 |
Why?
|
| Mutation | 2 | 2019 | 15918 | 0.010 |
Why?
|
| Proto-Oncogene Proteins c-ret | 1 | 2006 | 376 | 0.010 |
Why?
|
| Exercise | 1 | 2011 | 1209 | 0.010 |
Why?
|
| Age Distribution | 1 | 2005 | 727 | 0.010 |
Why?
|
| Reference Values | 1 | 2005 | 1143 | 0.010 |
Why?
|
| Papillomaviridae | 1 | 2006 | 646 | 0.010 |
Why?
|
| Administration, Oral | 1 | 2007 | 1620 | 0.010 |
Why?
|
| Drug Therapy | 1 | 2003 | 206 | 0.010 |
Why?
|
| Carcinoma in Situ | 1 | 2006 | 495 | 0.010 |
Why?
|
| Genotype | 1 | 2010 | 4266 | 0.010 |
Why?
|
| Medical Oncology | 1 | 2010 | 1462 | 0.010 |
Why?
|
| Research Design | 1 | 2009 | 1574 | 0.010 |
Why?
|
| Liver | 1 | 2010 | 3086 | 0.010 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2009 | 6264 | 0.010 |
Why?
|
| Biomarkers | 1 | 2010 | 5086 | 0.010 |
Why?
|
| Proto-Oncogene Proteins B-raf | 1 | 2006 | 1329 | 0.010 |
Why?
|
| Lymphatic Metastasis | 1 | 2006 | 4965 | 0.010 |
Why?
|
| Combined Modality Therapy | 1 | 2008 | 9049 | 0.010 |
Why?
|
| Immunohistochemistry | 1 | 2007 | 7790 | 0.010 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2007 | 7792 | 0.010 |
Why?
|